natgillin/translations-raw huggingface dataset:
Cardiovascular disease 
Kardiovaskularna bolest
This phenomenon is known as secondary failure, to distinguish it from primary failure, where the medicinal product is ineffective in an individual patient when first given. 
Ta pojava se naziva sekundarno zatajivanje, za razliku od primarnoga zatajivanja kada je lijek u pojedinih bolesnika neučinkovit već pri prvoj primjeni.
This resulted in a blood glucose-lowering effect throughout the meal period. 
Ovo je rezultiralo sniženjem razine glukoze u krvi tijekom razdoblja obroka.
Boxes of 30, 60, 90, 120, 180, 270 or 360 tablets in blisters are available. 
Dostupne su kutije s 30, 60, 90, 120, 180, 270 ili 360 tableta u blisterima.
• Thiazides (diuretics or ‘water pills'). 
- Tiazide (diuretici ili 'tablete za izmokravanje').
If you take too many tablets, your blood sugar may become too low, leading to a hypo. 
Ako uzmete previše tableta, može doći do prevelikog pada razine šećera u krvi, što vodi u hipoglikemiju.
• Ciclosporin (used to suppress the immune system). 
- Ciklosporin (za potiskivanje odgovora imunološkog sustava).
Do not use this medicine after the expiry date which is stated on the blister and outer carton. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na blisteru i vanjskom pakiranju.
Based on the experience with repaglinide and with other hypoglycaemic medicinal products the following adverse reactions have been seen: Frequencies are defined as: - Common (1/100 to <1/10) - Uncommon (1/1,000 to <1/100) - Rare (1/10,000 to <1/1,000) - Very rare (<1/10,000) - Not known (cannot be estimated from the available data) 
- Često (1/100 do <1/10) - Manje često (1/1000 do <1/100) - Rijetko (1/10 000 do <1/1000) - Vrlo rijetko (<1/10 000) - Nepoznato (ne može se procijeniti iz dostupnih podataka)
β-blocking medicinal products may mask the symptoms of hypoglycaemia. 
Beta-blokatori mogu prikriti simptome hipoglikemije.
• Itraconazole, ketokonazole (antifungal medicines). 
- Itrakonazol, ketokonazol (lijekovi protiv gljivica).
Your doctor will work out your dose. 
Vaš liječnik će odrediti koja Vam doza najbolje odgovara.
Rifampicin, a potent inducer of CYP3A4, but also CYP2C8, acts both as an inducer and inhibitor of the metabolism of repaglinide. 
Rifampicin, snažni induktor CYP3A4, ali i CYP2C8, djeluje i kao induktor i kao inhibitor metabolizma repaglinida.
The warning signs of a hypo may come on suddenly and can include: cold sweat, cool pale skin, headache, rapid heart beat, feeling sick, feeling very hungry, temporary changes in vision, drowsiness, unusual tiredness and weakness, nervousness or tremor, feeling anxious, feeling confused, difficulty in concentrating. 
Znakovi koji upozoravaju na hipoglikemiju mogu nastupiti iznenada i mogu obuhvaćati: hladan znoj, hladnu blijedu kožu, glavobolju, ubrzane otkucaje srca, mučninu, osjećaj jake gladi, privremene promjene vida, omamljenost, neuobičajen umor i slabost, nervozu ili nevoljno drhtanje, osjećaj tjeskobe, osjećaj smetenosti, poteškoće s koncentracijom.
There are no studies of repaglinide in pregnant women. 
Nisu provedena ispitivanja repaglinida u trudnica.
This lack of pharmacodynamic effect was observed with a sub-therapeutic dose of repaglinide. 
Izostanak farmakodinamičkog učinka opažen je pri primjenama supterapijskih doza repaglinida.
- Concomitant use of gemfibrozil (see section 4.5). 
- Istodobna primjena gemfibrozila (vidjeti dio 4.5).
The recommended maximum starting dose of patients transferred to repaglinide is 1 mg given before main meals. 
Preporučena maksimalna početna doza u bolesnika koji su prešli na repaglinid je 1 mg prije glavnih obroka.
However, no exact dosage relationship exists between repaglinide and the other oral hypoglycaemic medicinal products. 
Međutim, ne postoji izravna veza u doziranju repaglinida i drugih oralnih antidijabetika.
Repaglinide pharmacokinetics are characterised by low volume of distribution, 30 L (consistent with distribution into intracellular fluid) and is highly bound to plasma proteins in humans (greater than 
Farmakokinetika repaglinida karakterizirana je malim volumenom distribucije, 30 l (što je sukladno s distribucijom u unutarstaničnoj tekućini) i u velikom se postotku veže za proteine plazme u ljudi (više od 98%).
It cannot be excluded that other inducers, e.g. phenytoin, carbamazepine, phenobarbital, St John's wort, may have a similar effect. 
Ne može se isključiti da ostali induktori, primjerice fenitoin, karbamazepin, fenobarbital, gospina trava mogu imati sličan učinak.
Refraction disorder* 
Poremećaj refrakcije*
• Deferasirox (used to reduce chronic iron overload) 
- Deferasiroks (za snižavanje prekomjernog dugotrajnog nakupljanja željeza).
Alcohol can change the ability of Enyglid to reduce the blood sugar. 
Alkohol može promjeniti učinkovitost Enyglida u snižavanju razine šećera u krvi.
OTHER SPECIAL WARNINGS, IF NECESSARY 
DRUGO(A) POSEBNO(A) UPOZORENJE(A), AKO JE POTREBNO
Concomitant use of rifampicin and repaglinide might therefore induce a need for repaglinide dose adjustment which should be based on carefully monitored blood glucose concentrations at both initiation of rifampicin treatment (acute inhibition), following dosing (mixed inhibition and induction), withdrawal (induction alone) and up to approximately two weeks after withdrawal of rifampicin where the inductive effect of rifampicin is no longer present. 
Istodobna primjena rifampicina i repaglinida stoga može zahtijevati prilagodbu doze repaglinida, što treba činiti na osnovi pomnog praćenja koncentracije glukoze u krvi pri uvođenju terapije rifampicinom (akutna inhibicija), pri daljnjem doziranju (miješana indukcija i inhibicija), pri prestanku terapije (indukcija) te do približno dva tjedna nakon prestanka uzimanja rifampicina kada inducirajući učinak rifampicina više nije prisutan.
If you stop taking Enyglid 
Ako prestanete uzimati Enyglid
Doses are usually taken within 15 minutes of the meal, but the time may vary from immediately preceding the meal to as long as 30 minutes before the meal. 
Doze se obično uzimaju unutar 15 minuta prije obroka, iako vrijeme uzimanja može varirati od neposredno prije obroka do najviše 30 minuta prije obroka.
At such times, it may be necessary to discontinue repaglinide and treat with insulin on a temporary basis. 
U takvim slučajevima možda će biti potrebno prekinuti uzimanje repaglinida te privremeno uvesti terapiju inzulinom.
When a patient stabilised on any oral hypoglycaemic medicinal product is exposed to stress such as fever, trauma, infection or surgery, a loss of glycaemic control may occur. 
Kada je bolesnik, u kojega se stanje stabiliziralo primjenom bilo kojeg oralnog antidijabetika, izložen stresu kao što je vrućica, trauma, infekcija ili operativni zahvat, može doći do poremećaja regulacije glikemije.
You can take Enyglid with metformin, another medicine for diabetes, if your doctor prescribes it. 
Enyglid možete uzimati s metforminom, drugim lijekom protiv šećerne bolesti, ako ga liječnik propiše.
Repaglinide should only be prescribed if poor blood glucose control and symptoms of diabetes persist despite adequate attempts at dieting, exercise and weight reduction. 
Repaglinid treba propisivati samo kada loša regulacija glukoze u krvi i simptomi šećerne bolesti traju usprkos odgovarajućoj dijeti, tjelovježbi i smanjenju tjelesne težine.
A high interindividual variability (60%) in repaglinide plasma concentrations has been detected in the clinical trials. 
U kliničkim ispitivanjima uočena je visoka interindividualna varijabilnost (60%) u koncentraciji repaglinida u plazmi.
• Octreotide (used to treat cancer). 
- Oktreotid (za liječenje karcinoma).
Pharmaco-therapeutic group: Drugs used in diabetes, other blood glucose lowering drugs, excl. insulins, ATC code: A10BX02 
Farmakoterapijska skupina: lijekovi za liječenje šećerne bolesti, drugi lijekovi za snižavanje razine glukoze u krvi, osim inzulina, ATK oznaka: A10BX02
If you get a hypo (low blood sugar) 
Ako dobijete hipoglikemiju (niska razina šećera u krvi)
Repaglinide is indicated in adults with type 2 diabetes mellitus whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. 
Repaglinid je indiciran u odraslih sa šećernom bolešću tipa 2 u kojih se hiperglikemija više ne može zadovoljavajuće regulirati dijetom, smanjenjem tjelesne težine i tjelovježbom.
The blood glucose-lowering effect of oral hypoglycaemic medicinal products decreases in many patients over time. 
Učinak oralnih antidijabetika na snižavanje razine glukoze u krvi u mnogih bolesnika se s vremenom smanjuje.
Repaglinide was shown not to be teratogenic in animal studies. 
Ispitivanjima na životinjama su pokazala da repaglinid nije teratogen.
Skin and subcutaneous tissue disorders 
Poremećaji kože i potkožnog tkiva Preosjetljivost*
More severe hypoglycaemia with seizure, loss of consciousness or coma should be treated with intravenous glucose. 
Tešku hipoglikemiju uz napadaje, gubitak svijesti ili komu potrebno je liječiti glukozom primijenjenom intravenski.
The elevated insulin levels did not persist beyond the time of the meal challenge. 
Razine inzulina nisu ostale povećane nakon što je proteklo razdoblje obroka.
Allergy 
Alergija
Enyglid has been shown to lower the blood sugar, which helps to prevent complications from your diabetes. 
Enyglid snižava razinu šećera u krvi i time pomaže u sprečavanju komplikacija šećerne bolesti.
The following substances may reduce the hypoglycaemic effect of repaglinide: Oral contraceptives, rifampicin, barbiturates, carbamazepine, thiazides, corticosteroids, danazol, thyroid hormones and sympathomimetics. 
Hipoglikemijski učinak repaglinida mogu smanjiti ovi lijekovi: oralni kontraceptivi, rifampicin, barbiturati, karbamazepin, tiazidi, kortikosteroidi, danazol, hormoni štitnjače i simpatomimetici.
Eight percent of one dose of repaglinide is excreted through the kidneys and total plasma clearance of the product is decreased in patients with renal impairment. 
Osam posto pojedinačne doze repaglinida izlučuje se putem bubrega, a ukupni plazmatski klirens lijeka smanjen je u bolesnika s oštećenjem funkcije bubrega.
Repaglinide metabolites are excreted primarily via the bile. 
Metaboliti repaglinida primarno se izlučuju putem žuči.
V. Holjevca 20/E 10450 Jastrebarsko Croatia 
Holjevca 20/E, 10450 Jastrebarsko, Hrvatska
The following substances may enhance and/or prolong the hypoglycaemic effect of repaglinide: Gemfibrozil, clarithromycin, itraconazole, ketoconazole, trimethoprim, ciclosporin, deferasirox, clopidogrel, other antidiabetic substances, monoamine oxidase inhibitors (MAOI), non selective beta blocking substances, angiotensin converting enzyme (ACE)-inhibitors, salicylates, NSAIDs, octreotide, alcohol, and anabolic steroids. 
Sljedeće tvari mogu pojačati i/ili produljiti hipoglikemijski učinak repaglinida: gemfibrozil, klaritromicin, itrakonazol, ketokonazol, trimetoprim, ciklosporin, deferasiroks, klopidogrel, drugi antidijabetici, inhibitori monoamino oksidaze (MAO inhibitori), neselektivni beta-blokatori, inhibitori angiotenzin konvertirajućeg enzima (ACE inhibitori), salicilati, NSAIL, oktreotid, alkohol i anabolički steroidi.
However, the benefit risk profile remains to be established when comparing to other combination therapies. 
Međutim, nije utvrđen omjer koristi i rizika u usporedbi s drugim kombiniranim terapijama.
• Nonsteroidal anti-inflammatory drugs (NSAID) (a type of painkillers). 
- Nesteroidne protuupalne lijekove (NSAIL) (vrsta lijekova protiv bolova).
Consequently metabolism, and by that clearance of repaglinide, may be altered by substances which influence these cytochrome P-450 enzymes via inhibition or induction. 
Posljedično tome metabolizam, a time i klirens repaglinida, može biti izmijenjen tvarima koje inhibiraju ili induciraju enzime citokroma P-450.
The starting dose of repaglinide is 0.5 mg, taken before main meals; titration is according to blood glucose response as for monotherapy. 
Početna doza repaglinida je 0,5 mg prije glavnih obroka; titriranje doze ovisi o razini glukoze u krvi kao i kod monoterapije.
Special care should be taken when inhibitors of both CYP2C8 and 3A4 are coadministered simultaneously with repaglinide. 
Poseban oprez potreban je u slučajevima kad se inhibitori oba enzima CYP2C8 i 3A4 primjenjuju istodobno s repaglinidom.
The concomitant use of gemfibrozil and repaglinide is contraindicated (see section 4.3). 
Istodobna je primjena gemfibrozila i repaglinida kontraindicirana (vidjeti dio 4.3).
Enyglid is an oral antidiabetic medicine containing repaglinide which helps your pancreas produce more insulin and thereby lower your blood sugar (glucose). 
Enyglid je oralni antidijabetik (lijek protiv šećerne bolesti za primjenu kroz usta), a sadrži repaglinid koji pomaže gušterači da stvori više inzulina te tako snižava šećer (glukozu) u krvi.
Please see If you get a hypo on what a hypo is and how to treat it. 
Pogledajte dio Ako dobijete hipoglikemiju kako biste znali što je hipoglikemija i kako se liječi.
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Germany KRKA - FARMA d.o.o., V. Holjevca 20/E, 10450 Jastrebarsko, Croatia 
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenija TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Njemačka KRKA - FARMA d.o.o., V.
Abnormal hepatic function, increased liver enzymes* 
Poremećaji funkcije jetre, porast jetrenih enzima*
No safety concerns were raised. 
Nije bilo dvojbi vezanih uz sigurnost.
The effect of ketoconazole, a prototype of potent and competitive inhibitors of CYP3A4, on the pharmacokinetics of repaglinide has been studied in healthy subjects. 
Proučavan je učinak ketokonazola, prototipa snažnog kompetitivnog inhibitora CYP3A4, na farmakokinetiku repaglinida u zdravih ispitanika.
• Phenytoin, carbamazepine, phenobarbital (used to treat epilepsy). 
- Fenitoin, karbamazepin, fenobarbital (za liječenje epilepsije).
As insulin sensitivity is increased in diabetic patients with renal impairment, caution is advised when titrating these patients. 
Budući da je osjetljivost na inzulin povećana u oboljelih od šećerne bolesti s oštećenjem funkcije bubrega, oprez je potreban pri titraciji doze u ovih bolesnika.
If you forget to take Enyglid 
Ako ste zaboravili uzeti Enyglid
Repaglinide is also indicated in combination with metformin in adults with type 2 diabetes mellitus who are not satisfactorily controlled on metformin alone. 
Repaglinid je također indiciran u kombinaciji s metforminom u odraslih sa šećernom bolešću tipa 2 koji nisu primjereno regulirani samim metforminom.
What you need to know before you take Enyglid 
Što morate znati prije nego počnete uzimati Enyglid
In vitro data indicate that repaglinide is metabolised predominantly by CYP2C8, but also by CYP3A4. 
Podaci in vitro ukazuju da se repaglinid uglavnom metabolizira s pomoću CYP2C8, ali i CYP3A4.
• Danazol (used to treat breast cysts and endometriosis). 
- Danazol (za liječenje cista u dojkama i endometrioze).
What you need to know before you take Enyglid). 
Što morate znati prije nego počnete uzimati Enyglid).
When repaglinide was given 24 hours after the last rifampicin dose, an 80% reduction of the repaglinide AUC was observed (effect of induction alone). 
Davanje repaglinida 24 sata nakon posljednje doze rifampicina rezultiralo je 80% nižom AUC repaglinida (učinak same indukcije).
Short-term administration of repaglinide may be sufficient during periods of transient loss of control in Type 2 diabetic patients usually controlled well on diet. 
Kratkotrajna primjena repaglinida može biti dovoljna tijekom razdoblja prolaznog gubitka regulacije glikemije u bolesnika sa šećernom bolešću tipa 2, koji su inače dobro regulirani dijetom.
In the case of concomitant use with other active substances refer to sections 4.4 and 4.5 to assess the dosage. 
U slučaju istodobne primjene s drugim djelatnim tvarima doziranje treba procijeniti na temelju navedenog u dijelovima 4.4 i 4.5.
• Beta blockers (used to treat high blood pressure orheart conditions). 
- Beta-blokatore (za liječenje povišenog krvnog tlaka ili bolesti srca).
• if you are allergic to repaglinide or any of the other ingredients of this medicine (listed in section 6). 
Nemojte uzimati Enyglid - ako ste alergični na repaglinid ili neki drugi sastojak ovog lijeka (naveden u dijelu 6).
Co-administration of 100 mg itraconazole, an inhibitor of CYP3A4, has also been studied in healthy volunteers, and increased the AUC by 1.4-fold. 
Istodobna primjena 100 mg itrakonazola, inhibitora CYP3A4, također je ispitivana u zdravih dobrovoljaca te je povećala AUC repaglinida 1,4 puta.
Seven days pre-treatment with rifampicin (600 mg), followed by coadministration of repaglinide (a single dose of 4 mg) at day seven resulted in a 50% lower AUC (effect of a combined induction and inhibition). 
Prethodna terapija rifampicinom (600 mg) tijekom 7 dana, a potom dodavanje repaglinida (pojedinačne doze od 4 mg), sedmoga je dana rezultiralo 50% nižom AUC (učinak je kombinacija indukcije i inhibicije).
Repaglinide acts through a distinct binding site with a short action on the β-cells. 
Repaglinid se vezuje na posebna vezna mjesta i kratkotrajno djeluje na β-stanice.
If you have a hypo that makes you pass out, or a lot of hypos, talk to your doctor. 
• Ako imate hipoglikemiju od koje gubite svijest ili učestale hipoglikemije, obratite se svom liječniku.
• Keep this leaflet. 
- Sačuvajte ovu uputu.
Since the safety profile of this combination has not been established with dosages higher than 0.25 mg for repaglinide and 320 mg for trimethoprim, the concomitant use of trimethoprim with repaglinide should be avoided. 
Budući da sigurnosni profil ove kombinacije nije utvrđen za doze repaglinida iznad 0,25 mg i trimetoprima iznad 320 mg, istodobnu primjenu trimetoprima s repaglinidom treba izbjegavati.
Repaglinide is given preprandially and is titrated individually to optimise glycaemic control. 
Repaglinid se uzima prije obroka uz individualnu titraciju doze kako bi se postigla optimalna regulacija glikemije.
This is particularly important in those who have reduced or absent awareness of the warning signs of hypoglycaemia or have frequent episodes of hypoglycaemia. 
To je osobito važno u osoba u kojih su upozoravajući simptomi hipoglikemije slabije izraženi ili izostaju te u osoba s učestalim hipoglikemijama.
The resulting increased calcium influx induces insulin secretion from the β-cell. 
Posljedica toga je porast unosa kalcija što potiče sekreciju inzulina iz β-stanica.
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia 
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenija
not affected by renal disorders (see section 5.2). 
Na repaglinid ne utječu poremećaji bubrega (vidjeti dio 5.2).
Use of repaglinide in case of secondary failure to insulin secretagogues has not been investigated in clinical trials. 
Primjena repaglinida u slučaju sekundarnog zatajivanja lijekova koji potiču izlučivanje inzulina nije bila ispitivana u kliničkim ispitivanjima.
Repaglinide lowers the blood glucose levels acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning β-cells in the pancreatic islets. 
Repaglinid brzo snižava razinu glukoze u krvi potičući otpuštanje inzulina iz gušterače, a taj učinak ovisi o funkciji β-stanica otočića gušterače.
• Oral contraceptives (birth control pills). 
- Oralne kontraceptive (tablete za sprečavanje začeća).
• The dose may be adjusted by your doctor by up to 4 mg to be taken immediately before or up to 30 minutes before each main meal. 
- Liječnik Vam može povećati dozu do 4 mg, koju trebate uzimati neposredno prije ili do 30
Trials of combination therapy with NPH insulin or thiazolidinediones have been performed. 
Provedena su ispitivanja u kombiniranoj terapiji s NPH inzulinom ili tiazolidindionima.
Plasma repaglinide levels decreased rapidly, and low concentrations were seen in the plasma of Type 2 diabetic patients 4 hours post-administration. 
Razina repaglinida u plazmi je naglo pala te je u plazmi bolesnika sa šećernom bolešću tipa 2 izmjerena niska koncentracija 4 sata nakon njegove primjene.
Each tablet contains 0.5 mg, 1 mg, 2 mg repaglinide. 
Jedna tableta sadrži 0,5 mg, 1 mg, 2 mg repaglinida.
If concomitant use is necessary, careful monitoring of blood glucose and close clinical monitoring should be performed. 
Ako je neophodna istodobna primjena, potrebno je pažljivo pratiti razinu glukoze u krvi i provoditi poman klinički nadzor.
The amount of Enyglid, food or exercise may need to be adjusted. 
Možda će biti potrebno uskladiti dozu Enyglida, prehranu ili tjelovježbu.
Co-administration of cimetidine, nifedipine, oestrogen, or simvastatin with repaglinide, all CYP3A4 substrates, did not significantly alter the pharmacokinetic parameters of repaglinide. 
Istodobna primjena supstrata CYP3A4 enzima, kao što su cimetidin, nifedipin, estrogen ili simvastatin, s repaglinidom nije značajno izmijenila farmakokinetičke parametre repaglinida.
• The other ingredients are: microcrystalline cellulose (E460); calcium hydrogen phosphate, anhydrous; croscarmellose sodium; povidone K25; glycerol; magnesium stearate; meglumine; poloxamer; yellow iron oxide (E172) only in the 1 mg tablets and red iron oxide (E172) only in the 2 mg tablets 
- Drugi sastojci su mikrokristalična celuloza (E460); bezvodni kalcijev hidrogenfosfat; umrežena karmelozanatrij; povidon K25; glicerol; magnezijev stearat; meglumin; poloksamer; žuti željezov oksid (E172) samo kod tableta od 1 mg i crveni željezov oksid (E172) samo kod tableta od 2 mg.
• Clopidogrel (prevents blood clots) 
- Klopidogrel (sprječava zgrušavanje krvi).
• If you have any further questions, ask your doctor or pharmacist. 
- Ako imate dodatnih pitanja, obratite se svom liječniku ili ljekarniku.
Repaglinide can be given in combination with metformin, when the blood glucose is insufficiently controlled with metformin alone. 
Repaglinid se može davati u kombinaciji s metforminom ako se primjenom samog metformina ne postiže dobra regulacija glukoze u krvi.
Repaglinide closes ATP-dependent potassium channels in the β-cell membrane via a target protein different from other secretagogues. 
Repaglinid zatvara o ATP-u ovisne kalijeve kanale u membrani β-stanica vezanjem za protein koji je različit od proteina na koji se vezuju drugi lijekovi koji potiču izlučivanje inzulina.
• Sympathomimetics (used to treat asthma). 
- Simpatomimetike (za liječenje astme).
How to take Enyglid 
Kako uzimati Enyglid
Talk to your doctor before taking Enyglid: 
Obratite se svom liječniku prije nego uzmete Enyglid: - Ako imate problema s jetrom.
Name and address of the manufacturer responsible for batch release 
Naziv i adresa proizvođača odgovornih za puštanje serije lijeka u promet
When these medications are administered to or withdrawn from a patient receiving repaglinide, the patient should be observed closely for changes in glycaemic control. 
Kad bolesnik koji uzima repaglinid započne s uzimanjem ili prestane uzimati gore navedene lijekove, potrebno je pomno pratiti promjene regulacije glikemije u bolesnika.
Dosage adjustment of these compounds when co-administered with repaglinide is therefore not necessary. 
Stoga nije neophodna prilagodba doze ovih lijekova pri istodobnoj primjeni s repaglinidom.
A dose-dependent decrease in blood glucose was demonstrated in Type 2 diabetic patients when administered in doses from 0.5 to 4 mg repaglinide. 
U bolesnika sa šećernom bolešću tipa 2, sniženje razine glukoze u krvi ovisno o dozi lijeka potvrđeno je pri dozama repaglinida od 0,5 do 4 mg.
If concomitant use is necessary, careful monitoring of blood glucose and close clinical monitoring should be performed (see section 4.4). 
Ako je istodobna primjena neophodna, potrebno je pažljivo pratiti razinu glukoze u krvi i provoditi poman klinički nadzor (vidjeti dio 4.4).
The recommended maximum single dose is 4 mg taken with main meals. 
Preporučena maksimalna pojedinačna doza koja se uzima s glavnim obrocima iznosi 4 mg.
Enyglid is not recommended in patients with moderate liver disease. 
Enyglid se ne preporučuje u bolesnika koji imaju srednje tešku bolest jetre.